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Submicron particlesThere is increasing interest in the use of so-called ‘extraﬁne’ aerosols to target the small airways in the
management of asthma and COPD. Using previously presented deposition data, we assessed whether
submicron (<1 lm) particles can improve central and deep lung deposition. Our data show instead that
particles in the range 1–3 lm are much more relevant in this respect. Based on this ﬁnding the Symbicort
Turbuhaler, Seretide Diskus, Rolenium Elpenhaler and Foster (Fostair) NEXThaler ICS/LABA combination
DPIs were tested in vitro as a function of the pressure drop (2, 4 and 6 kPa) across the inhaler. Obtained
ﬁne particle fractions (FPFs) <5 lm (as percent of label claim) were divided into subfractions <1, 1–3 and
3–5 lm. Differences of up to a factor of 4 were found between the best (Turbuhaler) and worst perform-
ing DPI (Elpenhaler), particularly for the FPF in the size range 1–3 lm. The NEXThaler, described as
delivering ‘extraﬁne’ particles, did not appear to be superior in this size range. The marked differences
in amount and size distribution of the aerosols between the devices in this study must cause signiﬁcant
differences in the total lung dose and drug distribution over the airways.
 2015 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Asthma and chronic obstructive pulmonary disease (COPD) are
characterized by airﬂow obstruction and chronic inﬂammation of
the respiratory airways. In the last few years, management of these
diseases has improved considerably, as a result of the introduction
of new drugs, drug combinations, drug administration devices and
management strategies. Inhaled corticosteroids (ICSs) are the
cornerstone of asthma and, to a lesser degree, COPD therapy
because of their long-term efﬁcacy and safety [1] but optimal
effects may be expected when an ICS is administered in combina-
tion with a long acting beta2-agonist (LABA) [2]. This has resulted
in an increasing number of ICS/LABA inhalers becoming available.
There is also a growing awareness of the importance of small air-
ways in asthma and COPD [3,4] and the existence of a wide range
of clinical phenotypes related to small airway involvement [5].
Small airways are those less than 2 mm in diameter, comprising
the ducts between generation 8 and the alveoli. It has been postu-
lated that ﬁner aerosols than those delivered by most currently
available inhalers may be needed to target these small airways
more effectively and by that, to achieve a better drug distribution
over the whole bronchial tree [6]. The origin of this idea may havebeen the ﬁndings in the literature when chloroﬂuorocarbon
(CFC)-based pressurized metered dose inhalers (pMDIs) containing
beclometasone dipropionate (BDP) were replaced by hydroﬂuo-
roalkane (HFA)-based pMDIs, as a response to environmental con-
cerns about the ozone layer in the 1990s [7]. It was shown that
with the HFA pMDI only half the BDP dose is needed compared
with CFC pMDI for effective treatment of moderate asthma [8,9].
The effect was attributed to the much ﬁner aerosol from the HFA
pMDI of which the particles had a mass median aerodynamic
diameter (MMAD) of 1.1 lm versus 3.5–4 lm for the CFC pMDI.
More devices delivering ﬁner aerosols have since become
available, most of them being HFA solution pMDIs [10–12].
The only ICS/LABA combination delivered so far as a ﬁne aerosol
from a pMDI and now from a dry powder inhaler (DPI) is the
BDP–formoterol combination in Foster (Fostair), from Chiesi
Pharmaceuticals [6]. The reported beneﬁt of so-called ‘extraﬁne’
aerosols from HFA pMDIs has resulted in the expectation that the
same improvement can be obtained with the dry small particle
aerosol from this new Foster (Fostair) NEXThaler DPI compared
to other DPIs with the same drug combination [6]. Several compar-
ative studies with these new devices have recently been reviewed
and it was concluded that treating the peripheral airways with
smaller drug particle aerosols achieves comparable, and in some
studies superior, efﬁcacy compared with larger particles [13,14].
A reduction in the daily ICS dose was also reported, in addition
to greater asthma control and quality of life in some of the
real-life studies.
144 A.H. de Boer et al. / European Journal of Pharmaceutics and Biopharmaceutics 96 (2015) 143–151However, many questions remain to be answered before these
improvements can be attributed to improved peripheral and total
lung deposition from ﬁner aerosols compared to deposition of con-
ventional medications with larger particle size. It all starts with the
size deﬁnition for ‘extraﬁnes’. Different terms have been used to
describe ﬁner aerosols, such as ultraﬁne [10], extraﬁne [6] and,
more recently, small particle aerosols [13,14]. In this introduction,
only the term extraﬁnes will be used until the presentation of the
term ‘submicron particles’. Originally, extraﬁne aerosols from
newly developed HFA BDP formulations were characterized as hav-
ing an average diameter of 1.1 lm and a respirable fraction of
approximately 60% [15]. For the Foster NEXThaler, extraﬁne parti-
cles are described as having a MMAD of 1.4–1.5 lm [16], while the
deﬁnition for extraﬁne aerosols in the scientiﬁc literature has
recently been widened to particles with a diameter (D) < 2 lm
[13,14]. These different deﬁnitions partly overlap each other and
do not bring clarity about which aerosols are to be considered as
extraﬁne. Polydisperse aerosols from nearly all MDIs and DPIs
may contain substantial mass fractions of particles with
D < 2 lm. In contrast, devices producing the so-called extraﬁne
aerosols may also deliver signiﬁcant mass fractions of particles
with D > 2 lm. Therefore, aerosols from all currently available
MDIs and DPIs comprise both extraﬁne and non-extraﬁne particles
according to the most recent deﬁnition (D < 2 lm). The difference
is in the relative amounts of each of these fractions within the
aerosols. Hence, for polydisperse aerosols the term extraﬁne has
to be deﬁned not only in terms of size, but also in the quantiﬁed
mass fraction of these extraﬁnes in the aerosol. For this reason,
the rather imprecise terms extraﬁnes and small particle aerosols
will be used no further in this manuscript as an aerosol character-
ization term. Instead, a distinction will be made between submi-
cron (<1 lm) and micron range (>1 lm) particles of which the
micron range particles are divided into size fractions 1–3 lm and
3–5 lm to provide more detailed information about the structure
of the ﬁne particle fraction. The limit of 1 lm has been chosen
because submicron particles (D < 1 lm) in the particle concentra-
tion of therapeutic aerosols have a signiﬁcantly lower probability
of total lung and alveolar deposition than micron range particles
[17–19].
The inﬂuence of other variables on lung deposition involved
between the different devices used in comparative studies is also
relevant. Lung distribution and deposition are not governed by par-
ticle size alone, but also by particle velocity and residence time in
the lung [20]. The difference between the BDP CFC and BDP HFA
formulations in the previously mentioned MDI studies [7–9] is
not in the particle size alone, but more particularly in the velocity
with which the aerosol is released from the mouthpiece. The lower
velocity of the HFA aerosol plume leads to a considerable reduction
in impact force against objects in the ﬂow direction of the plume
and thus, a reduction in oropharyngeal deposition [21]. For BDP
from the HFA device (MMAD  1.1 lm) developed in the late
1990s, throat deposition was found to be much lower (30%) com-
pared with the CFC device (94%; MMAD  3.5–4 lm) [7].
Consequently, a much higher dose fraction remained available
for total lung deposition, the difference being (100–30)/(100–
94)  11.5-fold. Due to these different factors, the expectation that
a DPI delivering a ﬁner aerosol (MMAD  1.5 lm for the ﬁne parti-
cle fraction) at the same ﬂow rate as competitor devices with only
slightly coarser aerosols (MMAD  2.5–3 lm) can provide a more
effective deep lung deposition may be false.
Inhalers used in various comparative studies to investigate the
beneﬁt of ﬁner aerosols generally differ in more than particle size
and velocity alone [13,14]. There may also be differences in deliv-
ered (ﬁne particle) dose as percent of the label claim and many
new inhaler types (both MDIs and DPIs) produce not only ﬁner
aerosols, but also higher ﬁne particle doses [6,11]. In some recentlyreviewed studies [13,14] different types of inhalers (DPIs and
MDIs) were compared with each other, and also different drugs
in different strengths were involved and inhaled with different
inhalation manoeuvres. In addition, many clinical studies were
conducted without even recording the inspiratory ﬂow manoeu-
vres and the duration of the breath hold pauses. Differences in
resistance to air ﬂow through an inhaler can lead to marked differ-
ences in ﬂow rate at the same inspiratory effort [22]. With this
variable as a major determinant for drug distribution and deposi-
tion in the respiratory tract, considerable differences in clinical
effect may be expected, even if the aerosols from these devices
are exactly the same in vitro. Several patient factors may also be
involved, such as incorrect inhaler use [23], poor motivation or
adherence to the therapy or to the study (for out-of-clinic studies),
and severity of the disease, particularly when this affects
pulmonary function and lung ventilation. As a consequence of this
plurality of variables, it is virtually impossible to conclude which of
them is most responsible for an improved clinical effect. Hence,
clinical studies may be poor predictors for inhaler performance
regarding aerosol generation and delivery. Therefore, a different
approach seems necessary to investigate whether submicron parti-
cles can really contribute to improved therapeutic effects. The
effects of inhaler and patient variables, including the inhalation
manoeuvre, on aerosol generation, lung penetration, lung deposi-
tion and distribution and ultimately the clinical effect have to be
considered separately, as well as in their interactions with each
other. Judging an inhaler upon its potential to achieve a good
clinical effect has to start with measuring the aerosol properties
as a function of the ﬂow rate and the emission pattern of the
inhaler.
This manuscript has three aims: the ﬁrst is to discuss whether
submicron particles are likely to contribute to improved total
and deep lung deposition. A second and equally important aim is
to investigate which range of aerodynamic particle diameters is
most favorable for total and deep lung deposition at the range of
ﬂow rates to be expected through a medium to high resistance
DPI at moderate inspiratory effort (approx. 30–60 L/min). The third
aim is to evaluate the delivered ﬁne particle doses of four marketed
ICS/LABA combination DPIs in relation to the outcome of both pre-
vious aims.
For the assessment, data from a previous deposition study in
stable asthmatics were used and extrapolated towards particles
in the submicron range and basic aerosol physics were used to
check the validity of the extrapolations. Additionally, four DPIs,
all delivering an ICS/LABA combination, were tested at three differ-
ent pressure drops to measure their delivered ﬁne particle doses
(FPDs) and the structures of these FPDs as a function of the ﬂow
rate. FPFs < 1 lmwere computed to obtain more detailed informa-
tion about the presence and amount of submicron particles in the
aerosol. Detailed information about differences in total delivered
ﬁne particle masses (FPFs < 5 lm) and the structures of the
aerosols (FPFs < 1, 1–3 and 3–5 lm), as well as the ﬂow rate at
which the aerosols are delivered to the respiratory tract, is needed
to decide whether differences in clinical effect are likely the result
of any (or a combination) of these variables, or that of the involve-
ment of yet unknown or overlooked parameters and mechanisms.2. Materials and methods
2.1. Extrapolation of previously published deposition data
Usmani and co-workers measured lung deposition of
radiolabelled monodisperse salbutamol particles (1.5, 3.0 and
6.0 lm) in patients with stable asthma at two different ﬂow rates
[24]. They discriminated between oropharyngeal, central plus
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Fig. 1. Effect of particle size and inspiratory ﬂow rate on lung deposition for
monodisperse particles. Data derived from the Usmani study [24].
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period of 10 s to increase the lung residence time and, by that,
the particle fraction deposited by sedimentation. They also mea-
sured the mass fraction of particles exhaled and their data are repro-
cessed into Fig. 1. Since they studied only three individual particle
sizes, limited information was obtained about the deposition and
distribution of particles within the submicron range (D < 1 lm). To
further increase our understanding of particle behavior within this
range, extrapolation of the Usmani data was undertaken using basic
aerosol physics to derive and check the probabilities of inertial
impaction and sedimentation respectively within this range. The
results of this extrapolation and the procedures used for that are
presented and discussed in the results and discussion sections.
2.2. In vitro evaluation of four marketed DPIs
2.2.1. Materials
The four DPIs tested in this study were Symbicort 160/4.5 lg
Turbuhaler (SY-TU; AstraZeneca), Seretide 250/50 lg Diskus
(SE-DI, GlaxoSmithKline), Rolenium 250/50 lg Elpenhaler (RO-EL,
Elpen) and Foster/Fostair 100/6 lg NEXThaler (FO-NE; Chiesi).
Three different batches were tested and all inhalers were obtained
from themarket in different European countries depending on their
availability. Solvents, eluents and chemicals (high-performance
liquid chromatography [HPLC] grade) were supplied by Biosolve
Chimie (Dieuze, France), Merck (Darmstadt, Germany), VWR
International (Fontenay-sous-Bois, France) and Fischer Scientiﬁc
(Loughborough, UK). Ultra-pure water of Milli Q quality
(Millipore, Amsterdam, the Netherlands) was used for preparing
drug solutions and for rinsing the ﬁlter holder and impactor parts.
Delivered doses were collected on 50 mm glass ﬁber ﬁlters type
A/E (PALL Corporation, USA) and passed through 0.2 lmmembrane
ﬁlters Whatman, FP 30/0.2 CA-S (Dassel, Germany) for water or
PhenomenexRC 0.20 (Utrecht, theNetherlands) for organic solvents
prior to HPLC analysis. Active pharmaceutical ingredients for the
HPLC assays were provided by DFE Pharma (Goch, Germany), Teva
Pharmachemie (Haarlem, the Netherlands), Almirall Sofotec (Bad
Homburg, Germany) and AstraZeneca (Mölndal, Sweden).
2.2.2. Air ﬂow resistance
For inhalers, the air ﬂow resistance (R) is the proportionality
constant in the relationship between the square root of the pres-
sure drop (dP) across the device and the corresponding ﬂow rate
(U): dP = RU [25,26]. For all DPIs, the pressure drop was recorded
for the range of ﬂow rates between 0 and 90 L/min with incremen-
tal steps of 10 L/min. In this manuscript, values for L/min given are
for ambient conditions (1013 mbar and 20 C). Calibration was for
three devices per batch and each device was measured in triplicate,
yielding 27 recordings per type of inhaler. The inhalers wereconnected through a coupling ﬂange with a seal ring ﬁtting closely
around the mouthpiece to a thermal mass ﬂowmeter (5863S;
Brooks Instruments, the Netherlands). The pressure drop was mea-
sured immediately downstream of the mouthpiece with a differen-
tial pressure gauge (HBM PD1; Hottinger Baldwin Messtechnik,
Germany). Triplicate series per device were averaged to evaluate
the inter-batch variation.
2.2.3. Consistency of delivered dose (DD)
Consistency of DD at each pressure drop was determined for
10–20 doses per device, depending on the labelled number of
doses. For RO-EL 10 doses (blisters) were taken randomly per
batch. For the multi-dose (including multiple unit-dose) inhalers,
doses were taken from the beginning, middle and end of labelled
contents. Doses from the multi-dose inhalers were delivered with
an interval time of at least 30 s to prevent excessive tribocharge
of the device. Delivered doses were measured in 4 L of air drawn
through the inhalers at 2, 4 and 6 kPa. The inhalers were connected
to a ﬁlter system similar to that described by the US Pharmacopeia
(USP) 30 [31]. Delivered doses collected on 50 mm glass ﬁber ﬁlters
were dissolved by submersion of the ﬁlters in a 100 mL beaker. The
collection tube and coupling ﬂange were thoroughly rinsed with
the same solvents and the washings were added to the beaker
for HPLC analysis. For all drugs and drug combinations checks were
made to ensure that no adsorption occurred to the ﬁlters and that
the ﬁlters did not release leachables to affect the analysis.
Delivered doses were expressed as percent of label claim.
2.2.4. Consistency of delivered ﬁne particle dose (FPD)
Next Generation Impactors (NGIs) were used according to the
procedures given in the USP 30 [27] after mensuration by the sup-
plier (Copley Scientiﬁc, Nottingham, UK). Impactor cups were
coated using a mixture of Brij 35-p in ethanol with glycerol as
described previously [28]. The pre-separator was ﬁlled with
15 mL of a suitable solvent for the HPLC analysis. For the dispersion
tests, the inhalers were connected to a coupling ﬂange on the USP
induction port of the impactor with silicone rubber seals ﬁtting
closely around their mouthpieces. Delivered FPDs in 4 L air were
measured at 2, 4 and 6 kPa. After the impactor test, drug deposits
on the impactor stages were dissolved and the USP induction port
and pre-separator were rinsed thoroughly. FPDs presented are the
mean of 20–30 doses per kPa per device, depending on the labelled
number of doses per device and each test comprised 5 or 10 suc-
cessive doses analysed together to obtain sufﬁcient accuracy. For
the multi-dose DPIs, series of 5–10 doses for a test were taken from
the beginning, middle and end of labelled contents. Doses from the
multi-dose inhalers were delivered with an interval time of at least
30 s to prevent excessive tribocharge of the device. For RO-EL three
series of 10 doses were taken randomly per batch. FPDs were
expressed as percent of the label claim (yielding ﬁne particle frac-
tions: FPFs < 5 lm). Each FPF < 5 lm was divided into subfrac-
tions < 1, 1–3 and 3–5 lm.
2.2.5. HPLC procedures
Filter deposits (from consistency of DD measurements) and
impactor stage and induction port deposits (from consistency of
delivered FPD measurements) were analysed on an Agilent 1100
series HPLC (Waldbronn, Germany) using different solvents,
mobile phases (isocratic or gradient elution), columns and settings
for column temperature, pump ﬂow rate, injection volume and
wavelength, depending on the drug combination to be measured.
All assays were previously validated. Gauge lines were prepared
from pure drug combinations. For FO-NE the effect of magnesium
stearate on the assay was checked before starting the analyses.
It must be mentioned that different manufacturers use different
label claims for their products. Label claims may refer either to
146 A.H. de Boer et al. / European Journal of Pharmaceutics and Biopharmaceutics 96 (2015) 143–151masses measured by dose measuring principles, respectively,
masses measured into blisters, or to delivered masses
(ex-mouthpiece doses). To complicate the situation even further,
some multi-dose DPIs measure higher powder quantities than
the label claim indicates. On the European market there seems to
be no consensus or good regulation in this respect and therefore,
DDs and FPFs expressed as percent of label claim are not fully
comparable.on
 3. Results and discussion
Different in vitro evaluation studies with some of the currently
marketed DPIs are known. The DPIs tested in various studies may
produce rather extreme differences in aerosol properties, but the
results from different studies usually cannot be compared with
each other because of the differences in testing conditions, data
processing and data presentation used. To make a comparative
evaluation regarding the most favorable size distribution for total
and deep lung deposition possible, we tested four ICS-LABA combi-
nation DPIs under precisely the same conditions (2, 4 and 6 kPa)
and used the same data presentation for all devices by computing
mass fractions of the delivered aerosols in the size ranges < 1, 1–3
and 3–5 lm. This is breaking with a tradition according to which
only MMADs of delivered aerosols are given. We chose this
approach because MMADs do not provide information about the
size distribution of the aerosol or about the mass (or the size) frac-
tion of the dose for which the MMADs were computed. We com-
puted MMADs only for the FPFs < 5 m obtained at 4 kPa (Table 2).
Also, many different lung deposition simulation studies in the
past have shown which particle diameters have the highest depo-
sition probability in simpliﬁed lung models, as described byWeibel
and various others [29] as a function of the most relevant ventila-
tory parameters, including particularly the inhaled volume, ﬂow
rate and residence time [30,31]. Various empirical relationships
and deposition parameters have been derived to mathematically
ﬁt the deposition behavior of inhaled particles [17,20]. However,
many of these relationships and parameters were derived for depo-
sition during tidal breathing instead of deep inhalation through a
DPI, whereas the human lung is much more complex than the sim-
pliﬁed Weibel cascade of bifurcating tubes. The approach in this
study is different, using experimental deposition data for monodis-
perse aerosol particles from inhalation at a moderate ﬂow rate,
similar to inhaling through a DPI [24]. These data are explained
and extrapolated towards the submicron range using basic aerosol
physics. For our computations and discussion we assumed that no
uncontrolled or unknown effects such as condensational or hygro-
scopic particle growth and/or tribocharge effects in the in vivo
deposition study occurred. Several studies have shown that such
effects can signiﬁcantly affect lung delivery for orally inhaled aero-
sols [32–34].0
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Fig. 2. Percent oropharyngeal deposition as a function of the impaction parameter
(IP = qD2U). Data points derived from the Usmani study [24].3.1. Evaluation of previously published deposition data
The drug dose deposited in the lungs depends on the delivered
lung dose and the dose fractions lost by deposition in the orophar-
ynx and by exhalation. The probability of a particle being deposited
in the oropharynx can be predicted with the impaction parameter
(IP) which is the product of a particle’s density (q), the square of its
diameter (D) and its velocity (U). In practice, the ﬂow rate (U) can
be used instead of the velocity for the computations when the
same inhaler is used for all experiments and a linear proportional-
ity exists between U and U [32]. Usmani et al. used monodisperse
particles (q = 1) with aerodynamic diameters of 1.5, 3 and 6 lm
[24] and because they presented the mean ﬂow rates at which
these particles were inhaled, mean IP-values for their aerosolscan be computed. The relationship in Fig. 2 between the computed
impaction parameters and the experimentally obtained oropha-
ryngeal deposition values (from Fig. 1) enables a realistic estima-
tion of oropharyngeal depositions for smaller particle diameters
towards zero. Using this relationship oropharyngeal deposition
values were assessed for particle diameters 0.6, 0.8, 1.0 and
1.25 lm at 31 and 67 L/min.
Small particles (D < 1–2 lm) deposit primarily by sedimenta-
tion in the periphery of the lung [30]. The probability of sedimen-
tation depends on the particle’s terminal settling velocity (UTS), the
distance (H) of a particle to an airway wall (below the particle) and
the residence time (t) given for settling. Improving the settling of
small particles in the respiratory tract can thus be achieved by
increasing their residence time in the peripheral airways (i.e. by
elongating the breath hold pause after deep inhalation). If the dis-
tance (H) is greater than the product of time and settling velocity
(H > UTSt), the particle may be exhaled again. Therefore, for a par-
ticle at a given distance from the airway wall and a ﬁxed residence
time in the lungs, the chance of being deposited depends on the
terminal settling velocity, which is achieved when the force of
gravity is in equilibrium with the Stokes’ drag or resistance force.
The terminal settling velocity decreases exponentially with
decreasing particle diameter {UTS = Fu(D2)} and the time needed
to travel a ﬁxed distance increases correspondingly. Because the
chance of being exhaled for the smallest particles in the aerosol
is inversely proportional to the chance of being deposited by sedi-
mentation, the fraction exhaled shows basically the same depen-
dence on the particle diameter as the time to fall a certain
distance. Particles of 3 lm require a residence time of only 1.6 s
to fall across the diameter of a respiratory bronchiole (0.45 mm),
but this time increases to 12.8 s and 511 s for 1.0 and 0.1 lm par-
ticles respectively (with correction of the Stokes’ drag force for the
slip ﬂow) [20]. In Fig. 3 the time to fall a distance equal to the
diameter of a respiratory bronchiole is plotted for particles in the
size range from 0.4 to 6 lm. The relationship is shown to illustrate
the steep increase in this time for submicron particles. For such
small particles the time to travel across the diameter of a respira-
tory bronchiole becomes signiﬁcantly longer than the (average)
attainable breath hold pause. Fig. 3 also shows the exhaled frac-
tions of 1.5, 3 and 6 lm particles from the Usmani study [24]
and the relationship between the fraction exhaled and particle
diameter shows more or less the same trend as the settling velocity
for these particle diameters. This trend can be extended into the
range of submicron particles by roughly following the trend for
the settling time and using real in vivo (and simulated) deposition
data presented in the literature for reﬁnement [20,29–31].
Literature data show a minimum lung deposition efﬁciency for
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what can be expected on the basis of an exponentially increasing
settling time (Fig. 3). It must be recognized that there is no con-
stant proportionality between settling time and fraction exhaled
in Fig. 3, as the deposition efﬁciency of 1.5 lm particles is less
inﬂuenced by inertial deposition than that of 3 and 6 lm particles.
Moreover, when the particle size approaches that of the surround-
ing air molecules, the settling time becomes inﬁnite whereas depo-
sition efﬁciency increases again due to diffusion or Brownian
motion [20,30]. For the assessment of the percent exhaled in
Fig. 3, we took account of this minimum in deposition efﬁciency.
Mass fractions of particles in this size range are extremely low in
therapeutic aerosols however, and, therefore, hardly contribute
to the lung dose. For that reason, our extrapolations in
Fig. 4A and B do not encompass this size range: we stopped at
0.6 lm.
The fractions deposited in the oropharynx together with the
fractions exhaled comprise the total aerosol fractions not available
for lung deposition, referred to as ‘losses’. Figs. 4A and B show the
sum of these losses from oropharyngeal deposition and exhalation
as a function of the particle diameter at 31 and 67 L/min respec-
tively, based on the Usmani study [24]. Obviously, the percentages
complementary to 100% represent the fractions deposited in the
lungs. Fig. 4 shows that the deposition fraction decreases dramat-
ically for particles in the submicron range. Such particles in thera-
peutic aerosols are mostly exhaled again and, therefore, it is highly
unlikely that they contribute to improved total and peripheral lung
deposition compared to aerosols consisting of particles in the
micron-range (D = 1–5 lm). The result is in agreement with vari-
ous theoretical deposition modeling studies showing that there is
minimum deposition for particles within the size range 0.1–1 lm
[30,31]. Figs. 4A and B show nearly the same fraction exhaled, as
sedimentation deposition is largely independent of the ﬂow rate
(Fig. 3), but signiﬁcantly higher oropharyngeal deposition fractions
and the increase in oropharyngeal deposition are largest for the
largest particles. This makes the peak of % lung deposition more
pronounced, whereas the particle size for which the peak is com-
puted is almost the same: at 67 L/min it shifts to 1.5 lm.
Therefore, the lung deposition percentages in Figs. 4A and B,
complementary to the exhalation and oropharyngeal deposition
percentages, have the highest values in the range of diameters
between 1.25 and 3.5 lm at low to moderate ﬂow rate, and
because the precise peak depends on the inhalation manoeuvre
and changes slightly towards lower diameters both at higher ﬂow
rates and at longer breath hold pauses we decided to adhere to the
proposed division into subfractions of <1, 1–3 and 3–5 lm.There is a compelling reason for not taking the values in Fig. 4 as
absolute. They are only indicative for the effect of particle size on
lung deposition behavior. Although they were derived from real
deposition data [24], aerosol deposition fractions from marketed
inhalers, particularly dry powder inhalers, may be completely dif-
ferent. They are most likely to be lower than those shown in
Figs. 4A and B for a number of different reasons. First of all, aerosols
from marketed inhalers are polydisperse and total lung deposition
for such aerosols is the sum of the deposition fractions for the indi-
vidual particle sizes in these aerosols. Total lung deposition also
depends on the mass fractions of each of these particle sizes in
the aerosol. Nearly all marketed dry powder inhalers, except the
Turbuhaler, make use of adhesive mixtures and their dispersion
during inhalation is rather incomplete. Only a fraction of the total
drug mass is liberated from the carrier particle surface within the
appropriate size range for effective lung penetration and deposi-
tion. Therefore, the mass fraction of ﬁne particles in the aerosol
may be even more important than their MMAD. High total mass
fractions of particles (FPFs < 5m) may contain more particles in
the optimal size range for lung deposition than low FPFs < 5 m,
even if the lower FPF < 5 m has a considerably lower MMAD.
Furthermore, lung deposition of the same aerosol may vary with
the inhaler design. Different mouthpiece designs may result in dif-
ferent jet effects and circulations, even at the same ﬂow rate and
this can affect the oropharyngeal deposition in particular [35].
Nevertheless, and irrespective of the absolute deposition values,
the effect of particle size on deposition can well be estimated from
Figs. 4A and B and it may be clear that high mass fractions of sub-
micron particles in the aerosol are not likely to contribute to
improved lung deposition.
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Fig. 5. Delivered doses (as percent of the label claim) from Symbicort Turbuhaler
(SY-TU), Seretide Diskus (SE-DI), Rolenium Elpenhaler (RO-EL) and Foster
NEXThaler (FO-NE) as function of the pressure drop. Mean of 30–60 doses per
kPa (from three batches). The spread bars indicate the batch variation (highest and
lowest individual doses measured). (A) corticosteroid and (B) bronchodilator
fractions.
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The four DPIs tested in this study all contain a similar combina-
tion of a bronchodilator drug (LABA) and an ICS, but they are differ-
ent in design and many other respects. All are originator devices,
except for the Rolenium Elpenhaler, with different formulations
of soft spherical pellets (Turbuhaler) and carrier-based adhesive
mixtures using different carrier products (the other three inhalers).
The Rolenium Elpenhaler was selected for this study because this
DPI is marketed as being equivalent to the Seretide Diskus and con-
tains the same drug combination in the same strengths as the
Diskus. Some of the DPIs tested (Turbuhaler and NEXThaler) are
multi-dose inhalers with a dose measuring system to be operated
by the patient; the Diskus is a multiple-unit dose inhaler with the
doses pre-metered in blisters. The Elpenhaler makes use of sepa-
rate formulations for both drugs stored in separate blisters
whereas all other devices contain one formulation with both drugs.
The formulation in the NEXThaler has been prepared with magne-
sium stearate as a force control agent [36]. The use of force control
agents enables the separation of the drug particles more easily
from the carrier crystals during inhalation and part of this water
insoluble excipient is inhaled. Only the Turbuhaler and
NEXThaler have a speciﬁc powder dispersion principle for the aero-
sol generation energized by the inspiratory ﬂow.
The resistances to air ﬂow and the ﬂow rates corresponding to a
pressure drop of 4 kPa of the four DPIs are presented in Table 1. The
data show that Turbuhaler and NEXThaler are of medium to high
resistance (4 kPa corresponds with 59 L/min) whereas Elpenhaler
(68.3 L/min) and Diskus (75.2 L/min) are of medium resistance
[37]. Nevertheless, these differences in resistance between all four
devices are relatively small and hardly of any inﬂuence on the
deposition pattern of particles with the same size (distribution).
Their in vitro delivered doses (DDs) are illustrated in
Figs. 5A and B. These DDs are expressed as percentage of the label
claim for ICS (Fig. 5A) and LABA (Fig. 5B) for three different pres-
sure drops: 2, 4 and 6 kPa. Values measured for both drugs are
from the same inhaler and same dose numbers at the same
pressure drop and generally well within the expected range of
75–90% of the label claim. The differences between individual
doses from the same inhaler (at all pressure drops) are quite con-
siderable: maximum and minimum individual doses indicated by
the spread bars may differ by as much as a factor of 2.
While the proportion of delivered dose is important, the ﬁne
particle fraction (FPF < 5 lm) within the delivered dose is consid-
ered a direct measure of the inhaler’s potential for lung deposition.
Fig. 6 shows these fractions as a percent of the label claim for ICS
and LABA respectively with the spread bars indicating the
extremes obtained. The Diskus and Elpenhaler delivered the lowest
proportions of particles <5 lm. FPFs from the Turbuhaler and
NEXThaler were 2–3 times higher at 4 and 6 kPa compared to
Diskus and Elpenhaler. The difference in ﬁne particle fractionsTable 1
Air ﬂow resistances and ﬂow rates corresponding to 4 kPa pressure drop across the
inhaler. Mean of three devices per batch a and three duplicate measurements per
device. Min and max represent the lowest and highest mean batch value.
DPI Air ﬂow resistance
(kPa0.5 min L1)
Flow rate at 4 kPa
(L min1)
Mean Min Max Mean Max Min
SY-TU 0.0340 0.0338 0.0343 58.8 58.3 59.2
SE-DI 0.0266 0.0240 0.0295 75.2 83.3 67.8
RO-EL 0.0293 0.0291 0.0295 68.3 68.7 67.8
FO-NE 0.0339 0.0334 0.0345 59.0 59.9 58.0
a For Symbicort Turbuhaler (SY-TU), Seretide Diskus (SE-DI), Rolenium
Elpenhaler (RO-EL) and Foster NEXThaler (FO-NE).
Fig. 6. Delivered ﬁne particle doses (FPFs < 5 lm as percent of the label claim) from
Symbicort Turbuhaler (SY-TU), Seretide Diskus (SE-DI), Rolenium Elpenhaler (RO-
EL) and Foster NEXThaler (FO-NE) as function of the pressure drop. Mean of 20–30
doses per kPa (from three batches). The spread bars indicate the highest and lowest
individual batches measured.between the Diskus and Elpenhaler shows furthermore that these
devices, presented to the market as equivalent, are in fact not com-
parable. The Diskus, Elpenhaler and NEXThaler show an almost
pressure drop-independent output for the ﬁne particle dose. In
contrast, FPF increases with increasing inspiratory effort for the
Turbuhaler. The increase is most pronounced between 2 and
4 kPa and is desirable to compensate for oropharyngeal losses
and a shift in deposition towards larger airways at higher ﬂow
rates [22].
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Fig. 8. Fraction of 1–3 lm particles as percent of label claim. For abbreviations and
numbers of doses, see Fig. 6.
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Fig. 9. Fraction of 3–5 lm particles as percent of label claim. For abbreviations and
numbers of doses, see Fig. 6.
Table 2
Fine particle (sub)fractions < 1, 1–3; 3–5 and 1–5 lm as percent of the label claim at
4 kPa. MMADs are for the fraction < 5 lm (at 4 kPa).
ICS
Fraction SY-TU
budesonide
SE-DI
ﬂuticasone
RO-EL
ﬂuticasone
FO-NE BDP
<1 lm 6.5 1.6 0.2 18.9
1–3 lm 29.1 13.9 6.6 22.2
3–5 lm 12.7 8.2 10.1 4.3
1–5 lm 41.8 22.1 16.7 26.5
<5 lm 48.3 23.7 16.9 45.4
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total ﬁne particle fractions (<5 lm), but also for the structures of
these fractions. Figs. 7–9 show the rather extreme differences in
these structures. The high fraction of particles <1 lm in the
NEXThaler (Fig. 7), on average more than one-third of the FPF
<5 lm, contributes to the low MMAD of the aerosol produced by
this device (Table 2) [16]. Submicron fractions in the aerosols from
the other inhalers are much lower and those in the aerosols from
the Diskus and Elpenhaler are almost negligible. Differences in
FPF <5 lm between the inhalers (Fig. 6) are also strongly reﬂected
in the differences in the fraction 1–3 lm (Fig. 8). For this fraction,
most relevant to total lung deposition (Fig. 4), Turbuhaler and
NEXThaler score best. Fractions within this size range from the
Elpenhaler are less than 25% and from the Diskus less than 50%
of those from the best scoring DPIs at 4 and 6 kPa. Differences in
the coarsest ﬁne particle subfraction 3–5 lm are least pronounced
(Fig. 9). This fraction may be more relevant to the LABA component
than to the ICS component as particles in this size range are known
to have a good bronchodilating effect when they are inhaled at a
moderate ﬂow rate [24]. The sum of the fractions 1–3 and
3–5 lm at 4 kPa (the total ﬁne particle fraction without the
submicron particles: FPF 1–5 lm) is given in Table 2.
The comparative in vitro evaluation part of the study shows that
the DDs of all four DPIs tested were fairly comparable in spite of
the fact that label claims are not deﬁned unambiguously
(Figs. 5A and B). In contrast, the delivered FPFs (<5 lm) differed
considerably (Fig. 6) and so did the structures of these FPFs
(Figs. 7–9). From DPIs with a higher FPF <5 lm, a higher total lung
deposition may be expected at the same pressure drop, particularly
when the resistances to air ﬂow are comparable and the ﬂow rates
at which the aerosols are delivered to the respiratory tract are
more or less the same (Table 1). Differences in the structure of
FPF are more likely to inﬂuence drug distribution in the airways,
including the oropharynx. It could be shown that DPIs delivering
ﬁner aerosols, such as the NEXThaler, contain particularly high
fractions of submicron particles in the aerosol. Such particles
<1 lm do pass the oropharynx effectively and travel into the bron-
chial tree. However, they have only a small chance of deposition
there and are predominantly exhaled again (Fig. 4) as a result of
the exponentially decreasing settling velocity with decreasing
aerodynamic particle diameter. Particles in the size range 1–
3 lm are much more relevant to total lung deposition (Fig. 4)
and the extreme differences in this size fraction between the inha-
lers, which all have comparable air ﬂow resistances, could be a
good indicator for a choice between the devices. For the efﬁcacy
of inhaled therapy, other variables are also important, however.
For instance, the differences in ﬂow dependence between the0.0
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Fig. 7. Fraction of submicron (<1 lm) particles as percent of label claim. For
abbreviations and numbers of doses, see Fig. 6.
MMAD (lm) 2.07 2.54 3.33 1.21
LABA
Fraction SY-TU
formoterol
SE-DI
salmeterol
RO-EL
salmeterol
FO-NE
formoterol
<1 lm 6.7 1.5 0.4 15.6
1–3 lm 25.6 12.8 6.8 29.0
3–5 lm 12.2 7.3 7.1 5.7
1–5 lm 37.8 20.1 13.9 34.7
<5 lm 44.5 21.6 14.3 50.3
MMAD (lm) 1.96 2.36 2.88 1.57devices may have an effect on consistency of the therapy. An
increasing ﬁne particle dose with increasing ﬂow rate is desired
for compensating at least partly for the increased oropharyngeal
losses (Fig. 4) and a shift in deposition towards larger airways
[22]. From this viewpoint, none of the inhalers tested should be
used at a higher pressure drop than 4 kPa. FPFs 1–3 lm and
3–5 lm are hardly further increased at higher pressure drops, in
150 A.H. de Boer et al. / European Journal of Pharmaceutics and Biopharmaceutics 96 (2015) 143–151contrast to oropharyngeal deposition, particularly for the largest of
the aerosol particles up to 5 lm (Fig. 1). Therefore, lung deposition
will not further be increased between 4 and 6 kPa. The increase in
FPF 1–3 and 3–5 lm between 2 and 4 kPa is highest for Turbuhaler
and even slightly negative for NEXThaler. Aerosol emission pat-
terns are also relevant to lung distribution but they have not been
investigated in this study.
For lung deposition other variables are also important however.
For instance, the differences in ﬂow dependence between the
devices may have an effect on the consistency of the therapy. An
increasing ﬁne particle dose with increasing ﬂow rate is desired
to compensate at least partly for the increased oropharyngeal losses
(Fig. 4) and a shift in deposition towards larger airways [22]. Only
the Turbuhaler delivers an increasing FPF <5 m (between 2 and
4 kPa) and this device should, therefore, not be operated at pressure
drops >4 kPa to obtain the most consistent therapy. For the Diskus,
Elpenhaler and NEXThaler maximal lung deposition may be
obtained at 2 kPa, but for Diskus and Elpenhaler, this is consider-
ably lower compared to Turbuhaler and NEXThaler. Not only the
amount and quality of the aerosol, but also several patient factors
are important. Patient factors are quite complex, particularly for
DPI use, and include gender, age and disease related factors as well
as compliance with correct inhaler use and adherence to the ther-
apy. Therefore, in vitro assessments may overestimate the quantity
of drug deposited in the lungs. There is also a wider variability in
lung deposition in vivo thanwould be predicted by in vitromeasure-
ments [38], and the relationship between deposition and effect, as a
function of the particle diameter, can only be studiedwhen all other
controllable variables are kept the same. This will be one of the
challenges for future research.
4. Conclusions
The steep increase in the fraction exhaled with decreasing
particle diameter for submicron particles shown in Fig. 3 suggests
that particles <1 lm are not suitable for inhalation. High mass
fractions of submicron particles contribute to a lower MMAD of
the aerosol, but such particles are also largely exhaled again as
can be concluded from previously presented in vivo deposition data
for monodisperse particles, extrapolated towards the submicron
range. Therefore, previously presented size deﬁnitions for
so-called ‘extraﬁne’ particles seem to be irrelevant; from the view-
point of clarity, ‘submicron’ is proposed as a well-deﬁned and
much more meaningful alternative. Lung deposition percentages
in Fig. 4 conﬁrm various lung deposition modeling studies that
the particle size range 1–3 lm is most favorable for total and deep
lung deposition, when such particles are inhaled at a moderate
ﬂow rate (approx. 30–60 L/min) and given sufﬁcient time for
settling in the most distal airways (preferably 10 s, following a
deep inhalation after maximal exhalation).
Considerable differences exist between the delivered ﬁne parti-
cle doses (FPF <5 lm), and their structures, from Symbicort
Turbuhaler, Seretide Diskus, Rolenium Elpenhaler and Foster
NEXThaler. The differences are most pronounced for the less favor-
able submicron (D < 1 lm) particle fractions and the more relevant
fractions 1–3 lm. The FPFs 1–3 lm vary by a factor of 4 between
the extremes in this study with Turbuhaler and NEXThaler being
much better than Diskus and Elpenhaler. In contrast, most mass
fractions of particles 3–5 lm are of same order of magnitude. On
the basis of these differences in ﬁne particle output, signiﬁcant
differences in delivered lung dose and drug distribution over the
respiratory tract between the inhalers may be expected when they
are operated correctly. The ﬁne particle fractions at the same
pressure drop in this study are directly comparable as they are
delivered at roughly the same ﬂow rate, due to the comparable
resistances to air ﬂow for all four DPIs.Conﬂict of Interest Statement
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